Exploring YOLT-203 for treating Type 1 Primary Hyperoxaluria

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical exploration focuses on the safety and tolerability of YOLT-203 in patients with Type 1 Primary Hyperoxaluria (PH1). It is a single-arm, open-label trial that involves a dose-escalation and dose-expansion approach, assessing the effects of a single dose on plasma oxalate levels. Participants will undergo a screening period of up to 60 days, followed by treatment and a safety follow-up extending to 52 weeks. The study aims to determine the optimal biologically effective dose based on safety and efficacy data collected during the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The age is ≥ 2 years old at the time of signing the informed consent.
* Have AGXT gene mutations and be diagnosed with primary hyperoxaluria (PH1); eGFR ≥ 30 ml/min/1.73m2.
* At least 2 times of 24-hour urinary oxalate excretion ≥ 0.7 mmol/1.73m2/day or the ratio of urinary oxalate to creatinine in a single urine collection must be higher than the upper limit of normal (ULN) for the corresponding age.
* If treated with vitamin B6, the treatment has been stable for 90 days before enrollment in the study and is willing to maintain the stable treatment plan unchanged during the study.
* The patient himself/herself or the guardian voluntarily signs the informed consent.

Exclusion Criteria:

* The investigator judges that there is clinical evidence of systemic extra-renal oxalate deposition.
* Have any of the following laboratory parameter assessment results at screening:

  1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2 x the upper limit of normal (ULN).
  2. Total bilirubin \> 1.5 x ULN. If the increase in total bilirubin is caused by diagnosed Gilbert's syndrome and the total bilirubin \< 2 x ULN, it is eligible.
  3. International normalized ratio (INR) \> 1.5 (Patients on oral anticoagulants \[such as warfarin\] and with INR \< 3.5 will be allowed to participate).
* Known to have active human immunodeficiency virus (HIV) infection; or have evidence of current or chronic hepatitis C virus (HCV) or hepatitis B virus (HBV) infection.
* The estimated glomerular filtration rate (GFR) at screening is less than 30 mL/min/1.73m² (For patients ≥ 18 years old, it will be calculated according to the Modification of Diet in Renal Disease \[MDRD\] formula; for patients \< 18 years old, it will be calculated according to the Schwartz bedside formula). See the attachment.
* Have received an investigational drug within the last 30 days or 5 half-lives (whichever is longer) before the first administration of the study drug, or have participated in the follow-up of another clinical study before randomization.
* Have a history of kidney or liver transplantation.
* According to the investigator's opinion, have other medical conditions or comorbidities that may interfere with study compliance or data interpretation.
* Have a history of multiple drug allergies or allergic reaction history to oligonucleotides or LNP.
* Have a history of subcutaneous injection intolerance.
* Unwilling to comply with contraceptive requirements throughout the study participation period until 6 months after the end of the main study trial.
* Female patients are pregnant, planning to become pregnant or breastfeeding.
* Unwilling or unable to limit alcohol consumption throughout the study. Alcohol consumption during the study exceeds 2 units per day (1 unit: approximately 125 ml of wine = approximately 29 ml of spirits = approximately 284 ml of beer, will be excluded.
* The investigator believes that there is a history of alcohol abuse within 12 months before screening.

Where it's running

• Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
  Shanghai, Shanghai Municipality, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Plasma DNA Methylation to Classify Kidney Masses Before Surgery

  This study tests a blood-based DNA methylation test to help distinguish malignant kidney cancers from benign kidney masses in adults who are planned for kidney surgery.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT07874542

• miRNA panel test to help diagnose prostate cancer

  A blood test using a microRNA panel is being tested to help diagnose prostate cancer in men who are suspected of having the disease.

  Recruiting RenJi Hospital · Shanghai · NCT07755592

• Comparing ClotTriever vs. aspiration thrombectomy for acute iliofemoral DVT

  This study tests whether the ClotTriever System clears clot better than aspiration thrombectomy in adults with acute iliofemoral deep vein thrombosis.

  Recruiting RenJi Hospital · Shanghai · NCT07622212

• Profunda Femoris Vein Thrombosis Clearance to Improve Outcomes of Endovascular Treatment

  This trial tests whether clearing a blockage in the profunda femoris vein during endovascular treatment helps keep the iliofemoral vein open and reduces post-thrombotic syndrome in adults with acute iliofemoral DVT.

  Recruiting RenJi Hospital · Shanghai · NCT07622199

• Growth and development in infants after liver transplant

  We will track how babies up to 1 year old grow and develop over time after a liver transplant to find patterns that can improve follow-up care.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT07574398

• Acute pancreatitis after percutaneous mechanical thrombectomy: a retrospective analysis

  This project will look at adult medical records to see how often acute pancreatitis happens after percutaneous mechanical thrombectomy for thrombotic peripheral vascular disease.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT07450898

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.